Alps Advisors Inc Incyte Corp Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $1,688 - $2,103	-33 Reduced 0.58%	5,687 $344,000
Q1 2024 May 14, 2024	BUY	$56.55 - $66.59 $323,466 - $380,894	5,720 New	5,720 $325,000
Q1 2020 May 06, 2020	SELL	$63.18 - $85.97 $279,381 - $380,159	-4,422 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$73.04 - $95.72 $14,023 - $18,378	-192 Reduced 4.16%	4,422 $386,000
Q3 2019 Nov 04, 2019	BUY	$72.82 - $86.52 $7,573 - $8,998	104 Added 2.31%	4,614 $343,000
Q2 2019 Aug 07, 2019	SELL	$73.52 - $88.7 $17,350 - $20,933	-236 Reduced 4.97%	4,510 $383,000
Q1 2019 May 01, 2019	BUY	$63.56 - $88.17 $301,655 - $418,454	4,746 New	4,746 $408,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.